Third Quarter 2022 Financial Results

November 3rd, 2022



moderna

Forward-looking statements and disclaimer

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: anticipated sales, including the timing of sales, under advance purchase agreements in 2022 and 2023 and the associated revenue, which may not be realized; expected new contracts for COVID-19 vaccines; the repurchase by Moderna of shares of its common stock under its repurchase programs; the timing of data from Moderna's ongoing studies and trials, including for personalized cancer vaccines, RSV, flu and Moderna's COVID-19 booster vaccines; early signs of potential clinical benefit for PA and GSD1a; anticipated upcoming global product launches; Moderna's collaboration with Merck to jointly develop and commercialize mRNA-4157; COVID market dynamics and Moderna's ability to meet market needs for fall booster season and the timing for deliveries of fall boosters; the applicability of the flu market as a proxy for the COVID market; the medical burden of endemic COVID-19 and the size of the annual COVID booster market; expectations regarding transitioning to a commercial market for COVID-19 vaccines in the U.S.; potential accelerated approval of mRNA-1010 (flu); Moderna's preparations for commercial sales in 2023; Moderna's capital allocation priorities; and Moderna's 2022 financial framework. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, each filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this presentation.

3Q22 earnings call agenda

1. **Business Review – Stéphane Bancel, CEO**
2. R&D/Clinical Programs – Stephen Hoge, M.D., President
3. Commercial Market – Arpa Garay, CCO
4. Financials – Jamey Mock, CFO
5. Looking Forward – Stéphane Bancel, CEO

Financial highlights 3Q22

Third quarter 2022 GAAP financial results

- Revenue: $3.4 billion
- Net income: $1.0 billion
- Cash and investments: $17 billion

2022 outlook

- Revenue from advance purchase agreements for anticipated delivery in 2022 expected to be $18 to $19 billion, following delay of certain deliveries into 2023 due to short term supply constraints

Share repurchase plans

- Repurchased 7.1 million shares for ~$1 billion (average price of $141) in Q3
- Completed $3 billion share repurchase program announced in February early in Q4
- Share repurchase program announced in August for an additional $3 billion is in effect
- Total of 23.6 million shares repurchased since first share repurchase program initially put in place in 2021 (4Q21 to 3Q22)

moderna

Pipeline highlights and advances

COVID booster vaccines

- Received authorizations for Spikevax bivalent original/Omicron BA.1 (mRNA-1273.214) in countries around the world, including the EU, UK and Japan
- Received authorizations for Spikevax bivalent original/Omicron BA.4/5 (mRNA-1273.222) in countries around the world, including the U.S., EU, UK and Japan

Flu & RSV vaccines

- Phase 3 flu vaccine immunogenicity trial in southern hemisphere fully enrolled; data expected in 1Q23; started Phase 3 flu vaccine efficacy trial in northern hemisphere
- RSV vaccine efficacy trial ongoing; data could come this winter depending on cases

Personalized cancer vaccine (PCV)

- Merck exercised option to jointly develop and commercialize mRNA-4157; Moderna received $250 million in 4Q and will share costs and profits; expecting Phase 2 data in 4Q

Rare diseases

- Shared interim data from Phase 1/2 studies for both PA and GSD1a; therapies well-tolerated to date, with encouraging early signs of potential for clinical benefit
- Announced a new development candidate, mRNA-3139, for Ornithine transcarbamylase deficiency (OTC), a rare genetic condition

moderna

Moderna as of November 2022

Pipeline

Commercial

Moderna COVID-19 Vaccine/Spikevax®, mRNA-1273.222 and mRNA-1273.214

Phase 3

COVID boosters, Flu, RSV, CMV

Phase 2

PCV, Zika, VEGF-A, next generation COVID booster

48 development programs

Programs in development

Respiratory vaccines

- **COVID variant boosters (variant-specific and bivalents)** launched
- **Older adults RSV** in Phase 3; **Pediatric RSV** in Phase 1
- **Flu (mRNA-1010)** in Phase 3; **Flu (mRNA-1020/-30)** in Phase 1/2
- **Flu + COVID, flu + COVID + RSV** and **flu + RSV** in Phase 1/2
- **hMPV + PIV3** in Phase 1b age de-escalation study
- **RSV + hMPV, Endemic HCoV** in preclinical

Latent vaccines

- **CMV** in Phase 3
- **EBV, HIV** in Phase 1
- **HSV**, **VZV** in preclinical

Public health vaccines

- **Zika** in Phase 2
- **Nipah** in Phase 1

mRNA therapeutics

15 medicines in 4 therapeutic areas

- **5 Immuno-Oncology**: PCV in Phase 2; KRAS, Triplet, IL-12, Checkpoint in Phase 1
- **7 Rare Diseases**: PA, MMA, GSD1a in Phase 1/2; PKU, CN-1, CF, OTC in preclinical
- **2 Cardiovascular Diseases**: VEGF-A in Phase 2; Relaxin in preclinical
- **1 Autoimmune Diseases**: PD-L1 in preclinical

Foundations

~3,700

employees[1]

Science 2022 TOP EMPLOYERS

8th

Consecutive year top employer by *Science*

15 commercial

subsidiaries across North America, Europe and Asia Pacific

~$17B

of cash and investments (unaudited)[1,2]

1. As of September 30, 2022
2. Cash and investments denotes cash, cash equivalents and investments

moderna

3Q22 earnings call agenda

1. Business Review – Stéphane Bancel, CEO
2. **R&D/Clinical Programs – Stephen Hoge, M.D., President**
3. Commercial Market – Arpa Garay, CCO
4. Financials – Jamey Mock, CFO
5. Looking Forward – Stéphane Bancel, CEO

Moderna has launched two vaccine boosters to meet different market needs across the largest markets

mRNA-1273.214

(25 µg of mRNA-1273 and 25 µg of Omicron BA.1)

- Induced significantly higher titers than mRNA-1273 against the BA.1 and BA.4/5 strains in a clinical trial conducted before the fall booster season
- Authorized in United Kingdom, Switzerland, Australia, Canada, European Union, Japan and other countries

mRNA-1273.222

(25 µg of mRNA-1273 and 25 µg of Omicron BA.4/5)

- Based on the BA.4/5 strain and was developed consistent with FDA guidance
- Authorized in United States, United Kingdom, Switzerland, Australia, Canada, European Union, Japan and other countries
- Phase 2/3 data expected in 4Q22

Respiratory vaccines: Combination vaccine (COVID + flu + RSV) Phase 1 started

- **COVID-19 variant boosters and next generation booster (mRNA-1283)** in development
- **Flu (mRNA-1010)** Phase 3 studies ongoing; **Flu (mRNA-1020/-30)** Phase 1/2 trial fully enrolled
- **Older adults RSV (mRNA-1345)** Phase 3, known as ConquerRSV, is ongoing; **pediatric RSV** in Phase 1 fully enrolled
- **Combination COVID + flu (mRNA-1073)** Phase 1/2 fully enrolled
- **Combination COVID + flu + RSV (mRNA-1230)** Phase 1/2 started
- **Announcing new vaccine candidate RSV + Flu (mRNA-1045):** Phase 1/2 started
- **Pediatric hMPV + PIV3** Phase 1b fully enrolled; **pediatric RSV + hMPV and endemic HCoV vaccine** are in preclinical



Phase 3 Flu and RSV vaccines continue enrolling

Flu vaccine (mRNA-1010)

- **Southern hemisphere immunogenicity study** in adults (18+) is fully enrolled (6,000 participants)
  - Readout expected in 1Q23
- Initial regulatory feedback supports an accelerated pathway for approval
- **Northern hemisphere efficacy study** in adults (18+) has enrolled >10,000 participants
  - Readout could come this winter, depending on number of cases accrued in the study and vaccine effectiveness

RSV vaccine (mRNA-1345)

- **Pivotal Phase 3 efficacy study** in older adults (60+) has enrolled >35,500 participants
  - Primary endpoints are **safety and vaccine efficacy**
- **Phase 3 efficacy trial could readout this winter,** depending on number of cases accrued in the study and vaccine effectiveness

Latent & public health vaccines: CMV vaccine ongoing in Phase 3 study

- **CMV vaccine** pivotal Phase 3 study, known as CMVictory, is ongoing
- **EBV vaccine (to prevent infectious mononucleosis)** Phase 1 is ongoing; **EBV vaccine (to prevent EBV sequelae)** in preclinical
- **HIV vaccines** Phase 1 trials are ongoing
- **HSV and VZV vaccines** in preclinical
- **Zika vaccine** ongoing in a Phase 2 study
- **Nipah vaccine** Phase 1 study, led by the NIH, is ongoing



mRNA therapeutics: Checkpoint vaccine started Phase 1

Immuno-oncology
- **PCV** Phase 1 ongoing; Phase 2 fully enrolled, data expected in 4Q 2022
- **KRAS** Phase 1 ongoing; evaluating next steps for the program
- **Triplet** ongoing in Phase 1
- **IL-12** after portfolio review AstraZeneca returns program; evaluating next steps for the program
- **Checkpoint vaccine** started Phase 1

Cardiovascular
- **VEGF** evaluating next steps for the program
- **Relaxin** in preclinical

Autoimmune
- **PD-L1** in preclinical

Rare diseases
- **PA, MMA** Phase 1/2 ongoing; enrolling additional cohorts
- **GSD1a** Phase 1/2 ongoing
- **CF** partner Vertex expects to submit IND in 2022
- **OTC, PKU, CN-1** in preclinical

Modality	Program	ID #	Preclinical development	Phase 1	Phase 2	Phase 3	Commercial	Moderna rights
Systemic secreted & cell surface therapeutics	Relaxin *Heart failure*	mRNA-0184						Worldwide
	PD-L1 *Autoimmune hepatitis*	mRNA-6981						Worldwide
Cancer vaccines	Personalized cancer vaccine (PCV)	mRNA-4157						50-50 global profit sharing with **Merck**
	KRAS vaccine	mRNA-5671						Worldwide
	Checkpoint vaccine	mRNA-4359						Worldwide
Intratumoral immuno-oncology	OX40L/IL-23/IL-36γ (Triplet) *Solid tumors/lymphoma*	mRNA-2752						Worldwide
	IL-12 *Solid tumors*	MEDI1191						Worldwide
Localized Regenerative Therapeutics	VEGF-A *Myocardial ischemia*	AZD8601						Worldwide
	Propionic acidemia (PA)	mRNA-3927						Worldwide
	Methylmalonic acidemia (MMA)	mRNA-3705						Worldwide
Systemic Intracellular Therapeutics	Glycogen storage disease type 1a (GSD1a)	mRNA-3745						Worldwide
	Ornithine transcarbamylase deficiency (OTC)	mRNA-3139						Worldwide
	Phenylketonuria (PKU)	mRNA-3283						Worldwide
	Crigler-Najjar syndrome type 1 (CN-1)	mRNA-3351						Provided to **ILCM** free of charge
Inhaled Pulmonary Therapeutics	Cystic fibrosis (CF)	VXc-522						**Vertex** to pay milestones and royalties

Encouraging early clinical signs in rare disease modality

As presented during September R&D Day

PA (mRNA-3927)

- 6 patient-years of experience on drug and **all participants eligible have decided to continue on Open Label Extension (OLE) Study**
- Generally **well-tolerated to date**
- **Reduction in biomarker** (3-HP levels) observed
- Encouraging data shows **decrease in the number of metabolic decompensation events (MDEs);** Initial discussions with regulators supportive of MDE as primary endpoint for a pivotal study

paramount study

GSD1a (mRNA-3745)

- Early data on **safety and pharmacodynamics are consistent and encouraging**
- In two patients, mRNA-3745 was **well tolerated to date**, and **showed extension of fast duration and normalization of glucose during fast**

balance TRIAL

Moderna R&D Day 2022 presentation link

moderna

PCV (mRNA-4157) Phase 2 trial results expected in 4Q22

Primary endpoint is recurrence free survival compared to pembrolizumab



- Randomized, placebo controlled, PCV + pembrolizumab (KEYTRUDA®) vs. pembrolizumab alone (2:1)
- Resected melanoma patients - high recurrence risk
- Primary endpoint = recurrence free survival (RFS)
- Trial was fully enrolled (~150 participants) in September '21: Data expected in 4Q22
- Merck exercised option to jointly develop and commercialize mRNA-4157

3Q22 earnings call agenda

1. Business Review – Stéphane Bancel, CEO
2. R&D/Clinical Programs – Stephen Hoge, M.D., President
3. **Commercial Market – Arpa Garay, CCO**
4. Financials – Jamey Mock, CFO
5. Looking Forward – Stéphane Bancel, CEO

Q3 2022 Sales of $3.1B, Year to Date Sales of $13.6B

Product Sales YoY Comparison

In USD Billions



Q3 2022 Product Sales: $3.1 billion

- United States: $1.0 billion
- Europe: $1.0 billion
- RoW: $1.1 billion

YTD September 30, 2022, Product Sales: $13.6 billion

- United States: $3.4 billion
- Europe: $4.5 billion
- RoW: $5.7 billion

Note: Product sales include FX and hedge impact

Key topics for COVID booster commercial outlook

1. The medical burden for endemic COVID is expected to be greater than the burden for flu
2. Annual COVID booster volumes could approximate flu vaccine volumes over time
3. Important factors to consider as we transition to a commercial market in the U.S.
4. Current 2023 signed contracts

   Outlook on expected contracts

Since October 2021, the substantial medical burden for COVID has been greater than flu's historical burden

Flu vs. COVID medical burden comparison in United States



Flu: Range covers the last 10 flu seasons before pandemic-related disruptions ('09/10 flu season to '18/19 flu season)

CDC uses a mathematical model to estimate the numbers of influenza illnesses, medical visits, hospitalizations, and deaths in the United States for each season. CDC flu estimates: 2009/10, All other seasons

COVID outcomes are actual count of deaths and hospitalizations reported to CDC. COVID death data; hospitalization data

As COVID transitions to endemic, annual COVID booster volumes could approximate flu vaccine volumes over time

Scenarios global COVID booster market
($USD billions)

Global volume (million doses)	Global average price per dose: $20	$30	$40
400	$8B	$12B	$16B
600	$12B	$18B	$24B
800	$16B	$24B	$32B

Annual flu market is 500-600M doses[1]

Key variables that will impact the COVID volume in 2023

- Medical need
- Viral evolution
- Public health authority recommendations
- Consumer motivation to vaccinate

(1) WHO, Global Vaccine Market Report

moderna

Transitioning to a commercial market in the U.S.

Important factors to consider as COVID vaccine market in U.S. shifts to a commercial market in 2023

- More fragmented customer base
- Less predictability in orders
- Seasonality of deliveries
- Moderna assuming full distribution costs
- Transitioning from multi-dose vials to single-dose presentation
- Increased innovation/R&D with bivalent approaches

COVID sales contracts in 2023

Advance Purchase Agreements

- United Kingdom
- Canada
- Switzerland
- Taiwan
- Kuwait

Total **~$2.5B**

Deferrals from ’22 contracts

- Japan
- European Union
- Switzerland
- United Kingdom
- South Korea
- Latin America
- Israel

Total **~$2.0 – 3.0B**

Expected new contracts

- **U.S. transitioning to commercial**
- **Potential for additional EU contract**
- **Japan fall contract**
- **Australia** (independent review recommends additional Moderna vaccine purchase)
- **New and existing customers in Asia and Latin America**
- **In discussion with COVAX**

COVID vaccine endemic outlook summary

The **medical burden of endemic COVID is expected to be larger than flu**

As COVID transitions to endemic, **annual COVID booster volumes could approximate flu vaccine volumes over time**

In 2023 as we transition to a commercial market in the US, **important factors (such as distribution and dose presentation) are changing**

2023 COVID confirmed contracts and deferrals of **$4.5-5.5 billion; additional orders expected** in US, EU, Japan and other countries

Advancing respiratory vaccine franchise

			Preclinical	Phase 1	Phase 2	Phase 3	Licensed
Respiratory Infectious Diseases	mRNA-1273	SARS-CoV-2					
	mRNA-1010	Seasonal Flu (HA)					Earliest 2023
	mRNA-1345	RSV (older adults)					Earliest 2023

- **COVID boosters**: Launched Omicron-targeting bivalent candidates
- **Flu**: Immunogenicity readout expected in 1Q23; efficacy readout possible this winter season
- **RSV**: Depending on RSV case accrual, efficacy readout possible this winter season

Respiratory infections are a top cause of death globally: COVID, flu and RSV have the highest medical burden among respiratory viruses

3Q22 earnings call agenda

1. Business Review – Stéphane Bancel, CEO
2. R&D/Clinical Programs – Stephen Hoge, M.D., President
3. Commercial Market – Arpa Garay, CCO
4. **Financials – Jamey Mock, CFO**
5. Looking Forward – Stéphane Bancel, CEO

Third quarter 2022 financial results

In $ millions, except per share amounts (unaudited)	Q3 2022	Q3 2021	Change (Q3 22 vs. Q3 21)	
Product sales	**$ 3,120**	**$ 4,810**	**$ (1,690)**	**(35)%**
Grant revenue	144	140	4	3 %
Collaboration revenue	100	19	81	426 %
Total revenue	**3,364**	**4,969**	**(1,605)**	**(32)%**
Cost of sales	1,100	722	378	52 %
Research and development	820	521	299	57 %
Selling, general and administrative	278	168	110	65 %
Total operating expenses	**2,198**	**1,411**	**787**	**56 %**
Income from operations	**1,166**	**3,558**	**(2,392)**	**(67)%**
Other income (expense), net	51	(6)	57	NM
Provision for income taxes	174	219	(45)	(21) %
Net income	**$ 1,043**	**$ 3,333**	**$ (2,290)**	**(69)%**
Earnings per share – Diluted	$ 2.53	$ 7.70	$ (5.17)	(67) %
Weighted average shares – Diluted	412	434	(22)	(5) %
Effective tax rate	14 %	6 %		

Year-to-date 2022 financial results

In $ millions, except per share amounts (unaudited)	2022 YTD ended 9/30/22	2021 YTD ended 9/30/21	Change (YTD '22 vs. YTD '21)	
Product sales	**$ 13,576**	**$ 10,740**	**$ 2,836**	**26 %**
Grant revenue	453	473	(20)	(4) %
Collaboration revenue	150	47	103	219 %
Total revenue	**14,179**	**11,260**	**2,919**	**26 %**
Cost of sales	3,498	1,665	1,833	110 %
Research and development	2,084	1,343	741	55 %
Selling, general and administrative	757	366	391	107 %
Total operating expenses	**6,339**	**3,374**	**2,965**	**88 %**
Income from operations	**7,840**	**7,886**	**(46)**	**(1)%**
Other income (expense), net	80	(11)	91	NM
Provision for income taxes	1,023	541	482	89 %
Net income	**$ 6,897**	**$ 7,334**	**$ (437)**	**(6)%**
Earnings per share – Diluted	$ 16.46	$ 17.00	$ (0.54)	(3) %
Weighted average shares – Diluted	419	431	(12)	(3) %
Effective tax rate	13 %	7 %		

Cash/ Investments and Cash Deposits (unaudited)



- **Cash, Cash equivalents and Investments as of September 30, 2022, at $17.0 billion,** down from $18.1 billion as of June 30, 2022

- **Balance of Cash deposits for future product supply as of September 30, 2022, at $3.8 billion**, below prior quarter driven by product deliveries against customer deposits

Cash and investments decreased, reflecting the share buybacks in Q3 of $1.0 billion and a federal tax payment of $0.8 billion

Moderna's capital allocation priorities

1. **Reinvest in the business** & accelerate investment in R&D, manufacturing infrastructure and company buildout



- **Phase 3 trials:** Flu, RSV, and CMV
- **48 development programs**

2. **Seek attractive external investment opportunities (licenses and/or M&A)** to further expand the reach of Moderna's technology

- **Disciplined approach** to evaluating investment opportunities to advance medicines for patients
- Consider **attractive strategic opportunities** in the following areas:
  1. New medicines that leverage our existing platform(s)
  2. New technologies and capabilities in our existing platform(s)
  3. New platform expansion, e.g., genomics

3. **Return capital to shareholders**

- **Repurchased 7 million shares in Q3 2022 for $1.0 billion; Q3 year-to-date repurchased 20 million shares for $2.9 billion**
- Completed $3 billion Feb 2022 authorization in October, and began to utilize the previously announced $3 billion Aug 2022 authorization

2022 updated financial framework

Sales	▪ **Advance purchase agreements** (APAs) for **expected delivery in 2022 of $18-19 billion,** reflecting deferrals of $2-3 billion into 2023
Cost of sales	▪ We now **expect full year 2022 reported cost of sales in the 26 – 28 percentage range**, upper end in the event of further charges due to product updates
R&D and SG&A Expenses	▪ We continue to **expect full year R&D and SG&A expenses of ~$4 billion**
Tax rate	▪ We continue to **expect an Effective Tax Rate for the full year in low to mid-teen percentage range**
Capital Expenditures	▪ We now **expect capital expenditures of ~$0.5 billion**

3Q22 earnings call agenda

1. Business Review – Stéphane Bancel, CEO
2. R&D/Clinical Programs – Stephen Hoge, M.D., President
3. Commercial Market – Arpa Garay, CCO
4. Financials – Jamey Mock, CFO
5. **Looking Forward – Stéphane Bancel, CEO**

Next 12 months priorities

1

Execute 2022 sales and prepare 2023 private market sales

2

Execute on late-stage clinical pipeline

- 4Q22 **PCV data**
- Phase 3 vaccine trials: **Flu, RSV and CMV**
- Advance **rare disease programs to pivotal**

3

Prepare for multiple commercial launches

- Preparations underway for **multiple vaccine launches** between 2023-2025
- Potential for **therapeutics programs to move quickly to pivotal and then to launch,** given high unmet need

Save the Date

ESG Day on
November 10, 2022



https://moderna-esg-day.open-exchange.net/registration

Our mission

To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.

Moderna's Respiratory Vaccines (Pipeline 1/3)

Modality	Program	ID #	Preclinical development / Phase 1 / Phase 2 / Phase 3 / Commercial	Moderna rights
Adults — Prophylactic vaccines	COVID-19 vaccine	**mRNA-1273/Spikevax®**		Worldwide
		mRNA-1273.214	Omicron (BA.1) variant + wild-type	Worldwide
		mRNA-1273.222	Omicron (BA.4/5) variant + wild-type	Worldwide
		mRNA-1273.529	Omicron (BA.1) variant	Worldwide
		mRNA-1273.351	Beta variant	Worldwide
		mRNA-1273.617	Delta variant	Worldwide
		mRNA-1273.211	Beta variant + wild-type	Worldwide
		mRNA-1273.213	Beta + Delta variant	Worldwide
		mRNA-1283	Next generation (2-5 °C)	Worldwide
	Flu vaccine	**mRNA-1010**		Worldwide
		mRNA-1020		Worldwide
		mRNA-1030		Worldwide
		mRNA-1011		Worldwide
		mRNA-1012		Worldwide
	Older adults RSV vaccine	**mRNA-1345**		Worldwide
	COVID + Flu vaccine	**mRNA-1073**		Worldwide
	COVID + Flu + RSV vaccine	**mRNA-1230**		Worldwide
	Flu + RSV vaccine	**mRNA-1045**		Worldwide
	Endemic HCoV vaccine	**mRNA-1287**		Worldwide
Adolescents & Pediatrics	COVID-19 vaccine (adolescents)	**mRNA-1273/Spikevax®**	TeenCOVE	Worldwide
	COVID-19 vaccine (pediatrics)	**mRNA-1273/Spikevax®**	KidCOVE	Worldwide
	Pediatric RSV vaccine	**mRNA-1345**		Worldwide
	Pediatric hMPV + PIV3 vaccine	**mRNA-1653**		Worldwide
	Pediatric RSV + hMPV vaccine	**mRNA-1365**		Worldwide

Moderna's Latent & Public Health Vaccines (Pipeline 2/3)

Modality	Program	ID #	Preclinical development	Phase 1	Phase 2	Phase 3	Commercial	Moderna rights
Latent vaccines	CMV vaccine	**mRNA-1647**						Worldwide
	EBV vaccine *(to prevent infectious mononucleosis)*	**mRNA-1189**						Worldwide
	EBV vaccine *(to prevent EBV sequelae)*	**mRNA-1195**						Worldwide
Prophylactic vaccines	HSV vaccine	**mRNA-1608**						Worldwide
	VZV vaccine	**mRNA-1468**						Worldwide
	HIV vaccines	**mRNA-1644**						Worldwide ***IAVI/others*** *funded*
		mRNA-1574						Worldwide ***BMGF/NIAID/ others*** *funded*
Public health vaccines	Zika vaccine	**mRNA-1893**						Worldwide ***BARDA*** *funded*
	Nipah vaccine	**mRNA-1215**						Worldwide ***NIH*** *funded*

Moderna's Therapeutics (Pipeline 3/3)

Modality	Program	ID #	Preclinical development	Phase 1	Phase 2	Phase 3	Commercial	Moderna rights
Systemic secreted & cell surface therapeutics	Relaxin *Heart failure*	**mRNA-0184**						Worldwide
	PD-L1 *Autoimmune hepatitis*	**mRNA-6981**						Worldwide
Cancer vaccines	Personalized cancer vaccine (PCV)	**mRNA-4157**						50-50 global profit sharing with **Merck**
	KRAS vaccine	**mRNA-5671**						Worldwide
	Checkpoint vaccine	**mRNA-4359**						Worldwide
Intratumoral Immuno-oncology	OX40L/IL-23/IL-36γ (Triplet) *Solid tumors/lymphoma*	**mRNA-2752**						Worldwide
	IL-12 *Solid tumors*	**MEDI1191**						Worldwide
Localized Regenerative Therapeutics	VEGF-A *Myocardial ischemia*	**AZD8601**						Worldwide
	Propionic acidemia (PA)	**mRNA-3927**						Worldwide
	Methylmalonic acidemia (MMA)	**mRNA-3705**						Worldwide
Systemic Intracellular Therapeutics	Glycogen storage disease type 1a (GSD1a)	**mRNA-3745**						Worldwide
	Ornithine transcarbamylase deficiency (OTC)	**mRNA-3139**						Worldwide
	Phenylketonuria (PKU)	**mRNA-3283**						Worldwide
Inhaled Pulmonary Therapeutics	Crigler-Najjar syndrome type 1 (CN-1)	**mRNA-3351**						Provided to **ILCM** free of charge
	Cystic fibrosis (CF)	**VXc-522**						**Vertex** to pay milestones and royalties